Corrected information: b4, g4, g7 additional information: h2, h6, h10 udi: (b)(4).As reported by the customer, the patient had discrepant glucose reading results.The complaint sample was not returned to nova; therefore, an evaluation of the sample could not be performed.However, nova was able to perform an evaluation on retain strips from the same lot.The device history record (dhr) reviews for the statstrip glucose test strip lot number 0319114309 and all meters provided by the customer, were performed by the quality control engineer.The review included an assessment of the production, testing, and release of the meters and test strip batch.No abnormalities or concerns were observed; the dhr indicated that the released product met all specifications.Nova previously performed a comprehensive study on four (4) different lots of statstrip glucose test strips, ages 3, 6, 12, and 18 months.The study evaluated samples with low glucose concentrations and high hematocrit concentrations to simulate venous whole blood neonatal blood specimens.The data meets the fda's acceptance criteria with much of the comparative data within+/- 5 mg/dl of the reference method and most within +/-10 mg/dl.This type of variability is expected against central laboratory systems.This shows that with proper sample collection and handling the system reports accurate results.Based upon this investigation, it was determined that the incident occurred probably due to user error, not following the proper specimen handling technique for neonatal capillary heelstick sampling (use of heel warmer and site preparation).Nova biomedical has previously acknowledged the deficiencies in customer awareness of proper heelstick sampling technique for neonates by revising ifus to provide additional guidance for site preparation when testing neonates.Customer training was also conducted by field support and no other actions are warranted at this time.Trends will be monitored for this or similar complaints.
|